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Abstract: As longevity increases, so does the global prevalence of cognitive dysfunction. 
Numerous lifestyle and/or dietary interventions such as omega-3 fatty acids have been sug-
gested to improve memory. Therefore, this study examined the consistency and strength of 
the impact of supplementation of omega-3 fatty acids on overall cognitive function using 
systematic reviews and meta-analytic methods. Of 905 studies retrieved from all searches, 
12 randomized controlled trials were included in the meta-analysis. There were differences 
between studies reporting outcomes for single memory function parameters. Subgroup analysis 
of doses used (low versus high) indicated that subjects receiving low (1.73 g/day) doses of 
omega-3 fatty acids had a significant reduction in cognitive decline rate (−0.07, 95% confidence 
interval −0.01, −0.02) but there was no evidence for beneficial effects at higher doses (+0.04, 
95% confidence interval −0.06, +0.14) compared with the placebo group. This study suggests 
that omega-3 fatty acids may be beneficial in preventing memory decline at lower doses.
Keywords: cognitive impairment, Alzheimer’s disease, dietary fatty acids, omega-3, 
docosahexaenoic acid
Introduction
The prevalence of dementia is increasing with increased life expectancy and longevity, 
and is estimated to reach over 34 million worldwide by 2025.1,2 In the UK, there are 
over 800,000 people living with dementia, of whom approximately 17,000 are under 
the age of 65 years, and it is estimated to increase to nearly one million by 2021 and 
approximately 1.7 million by 2051.2,3
Although a number of hypotheses have been put forward to explain the etiology of 
cognitive decline, the exact etiology of dementia is not fully understood and it is not 
clear what can be done to prevent memory loss.4–6 Nonetheless, the evidence indicates 
that a healthy diet and lifestyle may help to protect against dementia. There are a number 
of human studies reporting clear associations between lifestyle and late-life cognitive 
decline. In particular, exercising regularly, avoiding fatty foods, not smoking, drinking 
alcohol in moderation, and keeping mentally and socially active into old age may help 
to reduce the risk of developing vascular dementia and Alzheimer’s disease.7
The role of healthy diet has been well established in a number of chronic illnesses, 
including obesity, diabetes, cardiovascular disease, and several cancers. Interestingly, 
nutrition has also been linked to delaying the onset of Alzheimer’s disease or slow-
ing its progression.8–10 Amongst various nutritional elements, polyunsaturated fatty 
acids such as omega-3 are considered to exert positive effects on cognitive function. 
However, the outcome of published reports varies considerably between the studies 





depending on the cognitive para meters assessed, the study 
period, the selected population, and the omega-3 doses used. 
Apart from variations in sample and contextual characteris-
tics, inconsistencies in the effect of interventions may also 
arise as a result of other factors, including lack of sufficient 
power (inadequate sample size) to detect a difference, espe-
cially where the effect of the intervention under consideration 
is small. Some of these problems (eg, variations in participant 
characteristics and inadequate sample size) can be addressed 
in part by carefully bringing together all existing evidence on 
the intervention, critically examining the assembled studies 
based on quality and comparability, and where appropriate, 
pooling the results of methodologically similar studies by 
statistical synthesis. Thus, this study examined the impact of 
omega-3 supplementation on composite cognitive function 
using systematic reviews and meta-analytic procedures.
Materials and methods
search criteria
Electronic searches were conducted in PubMed, Web of 
Science (which included Medline and PsycINFO), and the 
Cochrane database of registered controlled trials. Reference 
lists of included articles were also searched. Appropriate 
search terms (key word and Medical  Subject Headings) 
were used, and retrieved searches were combined using 
relevant Boolean operators (OR, AND). Where appro-
priate, search terms were truncated using relevant wild 
cards to retrieve alternative forms of the search terms, 
thereby increasing sensitivity. Search terms used included: 
“omega-3 fatty acid”, “polyunsaturated fatty acid”, “dietary 
fatty acid”, “alpha linolenic acid” (ALA), “linolenic 
acid”, “eicosapentaenoic acid” (EPA), “docosapentaenoic 
acid” (DPA), “docosahexaenoic acid” (DHA), “fish oil”, 
“essential fatty acid”, “cognitive function”,  “cognitive 
dysfunction”, “cognitive impairment”,  “dementia”, 
“Alzheimer’s disease”, “memory function”, “memory 
impairment”, “memory loss”, “cognitive decline”, and 
“cognitive performance”.
Titles and abstracts of studies retrieved from searches were 
considered for inclusion independently by two  reviewers. Full 
texts of articles that seemed to meet the inclusion criteria 
were obtained for further scrutiny. Also, full texts of articles 
which could not be excluded with certainty based on the 
title and the abstract were obtained and scrutinized further 
for inclusion or otherwise. Differences in opinion between 
the two reviewers were resolved by consensus. Electronic 
searches and study selection were conducted from June 2011 
to September 2011.
Inclusion/exclusion criteria
We considered studies that reported the consumption or 
supplementation of any omega-3 fatty acids (ALA, EPA, 
DHA, DPA) or fish (or fish oil) and their relationship with 
cognitive function/decline. Studies included were random-
ized controlled trials (RCTs) reporting data on either healthy 
or clinical populations. Studies comparing omega-3 fatty 
acids versus control or placebo and reporting a measure of 
cognitive endpoints were included.
All forms of omega-3 fatty acid interventions were 
considered. Thus, interventions involving more than one 
component were included if the results for the omega-3 fatty 
acid component could be isolated. Interventions evaluating 
the effect of a single component of omega-3 fatty acid 
(eg, DHA, DPA, EPA, or ALA), combined omega-3 fatty 
acids (eg, DHA and EPA), or fish oil on cognitive function 
were also included. However, studies reporting omega-3 
fatty acids or fish consumption plus another active compound 
where data for omega-3 fatty acids or fish intake could not be 
isolated from the other active compound were not included. 
Also, studies reporting any reasonable length of follow-up, 
dosage of supplementation, or type of sample population 
(healthy or clinical) were included.
The main outcome of interest was the mean change 
in global memory or cognitive function determined by an 
appropriate measure or scale, such as the Mini-Mental State 
Examination (MMSE). Where results for global cognitive 
function were not apparent, an appropriate specific scale 
of cognitive function (eg, word recall, verbal fluency) was 
used. No secondary outcomes were considered. Studies 
that did not report any measure of cognitive function were 
excluded. Also, studies that did not report sufficient data 
to permit the computation of effect size (mean difference) 
were not included. There was no restriction on age of 
participants.
Data extraction and quality assessment
A data extraction form was used to collect relevant infor-
mation from individual studies. Information collected from 
studies included study methods and participant characteristics 
(eg, setting, population from which the sample was recruited, 
mean age), intervention/control characteristics, and study 
quality indicators such as randomization, blinding, treatment 
concealment, and dropouts (see Table 1). As shown in Table 2, 
relevant data on the outcome measures of interest (mean of 
cognitive outcome at baseline, mean of cognitive outcome 
at follow-up, and if reported, mean changes from baseline to 
follow-up and their respective standard deviations) were also 
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extracted. Although data on methodological quality indicators 
(eg, blinding, randomization, withdrawal/loss to follow-up) 
were extracted and are reported here, we did not actively rate 
the quality of studies included in this review.
statistical analysis
In most of the studies, changes in cognitive function from 
baseline were not reported. These values were therefore 
computed from the relevant data (number of participants, 
mean, and standard deviation) reported at baseline and at 
follow-up. This is a conservative approach as it overestimates 
the standard deviation for the respective studies. As shown 
in Table 1, the studies used different scales/instruments to 
measure cognitive function/decline. Thus, the standardized 
mean difference (SMD) was used to compute the pooled 
treatment effect comparing intervention and control groups. 
The SMD is expressed as the absolute difference in means 
of the intervention and control groups divided by the pooled 
standard deviation.
For subanalysis of examining effects of dose differences, 
median dose of supplementation (1.7 g/day) was computed 
and used to divide studies into two groups of low-dose 
(1.7 g/day) or high-dose (1.7 g/day).
Meta-analyses were conducted using the fixed effects 
model, as there was no evidence of heterogeneity in any 
of the pooled analyses conducted to justify the use of a 
random effects model. Pooled estimates were conducted 
for all studies combined as well as for study subgroups 
based on treatment dose ( median dose/ median dose), 
duration of intervention (short-term 6 months/long-
term 6 months), and types of study participants (healthy/
clinical population). The data were analyzed using the 
metan command in Stata version 9 (StataCorp LP, College 
Station, TX, USA).
Results
Description of included studies
As shown in Figure 1, 905 studies were retrieved from all 
the searches conducted and 12 RCTs were included in the 
meta-analysis. Table 1 shows details of the methodological 
and participant characteristics of the studies included in this 
review. Over half of the studies (n=7) were conducted in 
general or healthy populations.11–16 The others were  conducted 
in specific clinical or special populations  including people 
with: schizophrenia,17 various degrees of memory prob-
lems,18–20 depression,21 or pregnant women.22 Included studies 
varied in sample size, ranging from 53 subjects11 to 867 sub-
jects.16 Freund-Levi et al19 used a randomized, double-blind, 
parallel-group study design for the first 6 months and then 
open treatment for all participants thereafter. All other studies 
were double-blind, parallel-group RCTs. Five of the studies 
involved young adult/middle-aged samples (mean age 40 
years),11,14,17,21,22 and all other studies involved older popula-
tion samples (mean age 68 years).
Interventions were mostly presented as supplements in 
capsules as combinations of DHA and EPA,12,16,19–21 DHA 
only,11,13,15,18 EPA only,18 ALA (the dietary precursor of 
DHA),22 or fish oil.14 Duration of intervention and follow-up 
ranged from 4 weeks to 24 months (median 23 weeks) and 
daily consumed doses of a single or combined components 
of omega-3 fatty acids ranged from 0.58 g of combined 
DHA and EPA19 to 3.12 g of ALA.22 Loss to follow-up was 
reported in ten of the included studies, and ranged from 
3%12 to 27%.18
effect of omega-3 fatty acids  
on cognitive function/decline
Considering the results for individual studies included in 
this review, only Yurko-Mauro et al15 reported significant 
changes in measures of cognitive function/decline for all 
participants randomized to omega-3 fatty acid interven-
tion compared with placebo. Specifically, they found that 
participants  randomized to DHA scored significantly fewer 
errors in the Cantab® paired associate learning (PAL) 
measure compared with those randomized to placebo 
(mean difference −1.63±0.76; P=0.032) after 24 weeks of 
 supplementation. They also reported significant differences in 
other subscales of the Cantab measure but not MMSE scores 
between the intervention and placebo groups.
Some studies reported a significant effect of omega-3 
fatty acid supplementation only after detailed investigations 
were conducted within subgroups of study participants. For 
example, compared with their omega-3 fatty acid intervention 
group, Freund-Levi et al19 reported a significant decrease in 
MMSE scores (P=0.01) for their control group when sub-
group analysis was conducted for participants with very mild 
Alzheimer’s disease (MMSE 27 and Clinical Dementia 
Rating score 0.5–1). The change in MMSE scores for the 
omega-3 fatty acid group after 6 months of supplementa-
tion was −0.5 points (P0.05) compared with −2.6 points 
(P0.001) in the placebo group. Also, the placebo group 
experienced a significant worsening in cognitive function (as 
indicated by scores on the “delayed word recall” subscale of 
the Alzheimer’s Disease  Assessment Scale-Cognitive Sub-
scale [ADAS-cog]; P=0.007) compared with no change in 
the intervention group. Chiu et al20 also reported improvement 
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in cognitive function (indicated by reduced scores on 
ADAS-cog) in participants with mild cognitive impairment 
supplemented with omega-3 fatty acids compared with 
 placebo (−3.23±3.82 versus −0.37±1.4; P=0.03). The study 
by van de Rest et al12 also reported significant improvement 
in the cognitive domain of attention among apolipoprotein 





Measures of cognitive  
function used in current study
Indicator of cognitive  
improvement (↑↓)
Outcome of interest 
(intervention group)




PP stroop test (100%) 














ITT rBans ↑ (+) Bl, 75±15 Bl, 77±40
Final, 76±18 Final, 74±14
de Groot  
et al22






ITT/PP but results 
reported in PP
MMse (0–30 points) 
aDas-cog (0–85 points) 





Bl, 23.6 (22.8–24.4) 
Final, 22.8 (21.9–23.7) 
Bl, 25.7 (23.6–27.8) 
Final, 27.7 (25.4–30.0) 
Bl, 1.0 (0.9–1.1) 
Final, 1.1 (1.0–1.2)
Bl, 23.2 (22.4–24.0) 
Final, 22.4 (21.5–23.4) 
Bl, 27.2 (25.1–29.4) 
Final, 28.3 (26.0–30.6) 




PP Verbal fluency 



























PP used for cognitive 
function tests
cognitive function measured using 
various tasks. scores for simple  
reaction time is used




van de rest  
et al12
ITT WlT (immediate recall-75 
words)




































PP used in  
secondary analysis
aDas-cog 















ITT cVlT-total words recalled 
Immediate story recall 


















Bl, 19.8±5.1 Bl, 19.9±5.0
Final, 19.1±5.4 Final, 19.5±5.3
Notes: −This study used a cross-over design, thus results for first 6 months are compared; *P0.05. The upward arrows and (+) indicate cognitive improvement in cognitive 
outcome in intervention group compared to the control group. similarly, downward arrow and (−) indicate decline in cognitive outcome in intervention group compared 
to control group.
Abbreviations: Bl, baseline; cVlT, california Verbal learning Test; ITT, intention-to-treat analysis; nc, not clear from data; PP, per protocol analysis; cDr, clinical 
Dementia rating score; WlT, Word learning Test; WlTtot, total Words learning Test; MMse, Mini-Mental state examination: aDas-cog, alzheimer’s Disease assessment 
scale-cognitive subscale; rBans, repeatable Battery for the Assessment of Neuropsychological Status; CI, confidence interval; PAL, paired associate learning; RT, total 
interference from stroop test for speed and accuracy of processing.





E ε4 carriers and men supplemented with fish oil compared 
with controls. Another study13 reported significant within-
group change in cognitive function in the intervention group 
but not in the control group. Compared with baseline scores, 
participants in the intervention (DHA) group named sig-
nificantly more items (2.8) from a category within a minute 
after 4 months of supplementation. However, there was no 
improvement in the number of items (0.9) named by partici-
pants in the control group within the same period.
Pooled analysis involved 2,510 participants, with 1,298 
and 1,212 randomized to the intervention and control groups, 
respectively. The median duration of intervention was 23 
(range 4–96) weeks. As shown in Figure 2, results for all the 
studies combined were consistent with the individual findings 
from most studies. The pooled results showed no significant 
change in memory function following supplementation with 
omega-3 fatty acids or the component elements (pooled 
SMD −0.04, 95% confidence interval [CI] −0.09, +0.01). 
As shown in the forest plot of the meta-analysis, only one 
study (Yurko-Mauro et al15) showed significant improvement 
in cognitive function (based on the Cantab PAL measure) 
following omega-3 fatty acid supplementation (SMD −0.21; 
95% CI −0.3, −0.04).  Heterogeneity between studies was not 
statistically significant (χ2=11.99, df =23, P=0.97).
There were no significant differences in cognitive func-
tion between the intervention and control groups when 
pooled analyses were stratified by duration of follow-up 
([short-term 6 months SMD −0.08, 95% CI −0.16, +0.01]; 
[long-term 6 months SMD −0.03, 95% CI −0.09, +0.03]); 
type of participants included ([general/healthy population 
SMD −0.04, 95% CI −0.10, +0.01]; [diseased/clinical popula-
tion SMD 0.00, 95% CI −0.10, +0.09]). However, there was a 
statistically significant effect when analysis was stratified by 
905 Number of reports retrieved from all searches
Number of reports after duplicates removed
Number of reports included after screening titles
Number of reports included after screening abstracts
























































Favors omega-3 fatty acid supplementation Favors no supplementation (control)






















































de Groot et al22
Freund-Levi et al19
Freund-Levi et al19


















Measure SMD (95% CI) Weight (%)
Figure 2 Forest plot for omega-3 fatty acid supplementation and cognitive decline.
Abbreviations: aDas-cog, Alzheimer’s Disease Assessment Scale-Cognitive Subscale; CI, confidence interval; CVLT, California Verbal Learning Test; DDT, dementia 
detecting test; WlTtot, total Words learning Test; 15-WlMT, Word list (memory) Test; rBans, repeatable Battery for the assessment of neuropsychological status; 
MMse, Mini-Mental state examination; WlT, Word learning Test; Pal, paired associate learning; cDr, clinical Dementia rating; sMD, standardized mean difference; srT, 
simple reaction time.
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dose of supplementation, as shown in Figure 3. Compared with 
controls, there was a significant reduction in the rate of cogni-
tive decline in groups supplemented with low doses (1.73 g/
day) of omega-3 fatty acids (SMD −0.07, 95% CI −0.13, −0.02). 
There was no evidence of cognitive benefit for supplementation 
with higher doses of omega-3 fatty acids (SMD +0.04, 95% CI 
−0.06, +0.14). Further, no statistically significant heterogeneity 
was observed in any of the stratified analyses.
Discussion
There are a number of clinical forms of memory loss, with 
Alzheimer’s disease being the main contributor to the num-
ber of patients with dementia. The pathological signs of 
Alzheimer’s disease appears to be susceptible to the effects of 
DHA, an omega-3 polyunsaturated fatty acid that is essential 
for the development and maintenance of the prenatal brain 
and maintenance of vision in adults.23,24 Indeed, patients with 
established Alzheimer’s disease have decreased levels of 
DHA in their brain membrane.25,26 Therefore, it is plausible 
to assume that replenishment of DHA would have a positive 
impact on memory function. Nonetheless, the clinical trials 
published thus far have failed to provide a clear consensus on 
the impact of omega-3 supplementation on cognitive func-
tion. The information on the effects of omega-3 on memory 
function provided in the published literature varies accord-
ing to the parameter tested, study duration, and the baseline 
memory function of the subjects participating in the study. 
These variations ultimately exacerbate ambiguity with regard 
to the effects of omega-3 supplementation on memory func-
tion. Needless to say, memory health/cognition should be 
considered as the sum of the ability of an individual’s memory 
to respond to various cognitive parameters. Therefore, this 
study included a pooled analysis on data from 12 relevant 
published RCTs to determine whether or not omega-3 has 
any beneficial effects on memory function.
Of the 12 RCTs included in this study, four measured 
MMSE, three measured ADAS-cog, two measured the Stroop 
test, four measured various forms of the Word  Learning Test, 
two measured the Clinical Dementia  Rating, two measured 
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Figure 3 Forest plot of omega-3 fatty acid for low and high dose compared with no supplementation (control).
Abbreviations: aDas-cog, alzheimer’s Disease assessment scale-cognitive subscale; cVlT, california Verbal learning Test; DDT, dementia detecting test; WlTtot, 
total Words learning Test; 15-WlMT, Word list (memory) Test; rBans, repeatable Battery for the assessment of neuropsychological status; MMse, Mini-Mental state 
examination; WlT, Word learning Test; Pal, paired associate learning; cDr, clinical Dementia rating; sMD, standardized mean difference; srT, simple reaction time; cI, 
confidence interval.





the California Verbal Learning Test, one measured various 
tasks of simple reaction time, one measured the Repeat-
able Battery for the Assessment of  Neuropsychological 
Status, and one measured dementia detecting test, giving 
a total of 24 measurements of different parameters. Where 
a parameter was reported to be measured in more than one 
study (eg, MMSE, ADAS-cog, Stroop test, Word Learning 
Test, or Clinical Dementia  Rating) the data were not similar 
and variation did exist (Figure 2); however, pooling the data 
indicated a significant positive effect of omega-3 on overall 
cognitive function, at least for the six low dose studies (see 
top forest plot of Figure 3). This clearly indicates that  clinical 
trials investigating the impact of an agent on cognition cannot 
solely rely on testing specific parameters of cognition, but 
rather a comprehensive assessment of cognition should be 
included in any clinical trials examining memory function.
The published data examining the impact of omega-3 
supplementation has shown contrasting outcomes19,27 with 
no clear explanation. Therefore, in this study, we performed 
a subanalysis of 12 RCTs for two groups of low-dose 
(14 parameters assessed) and high-dose (10 parameters 
assessed) omega-3 usage. Interestingly, clear differences 
became apparent between the effects of low-dose and high-
dose omega-3 use on memory function. The sub analysis 
suggests that low-dose but not higher-dose omega-3 supple-
mentation has positive effects on cognitive function. This 
variation may in part explain the contrasting reports observed 
with clinical trials of omega-3 and cognitive function. 
However, what is important to note is the positive impact of 
low-dose omega-3 on memory. The mechanism(s) of effect 
remains to be elucidated, but may include reducing the pro-
duction of amyloid beta-protein,28,29 thus reducing the plaque 
burden on neuronal cells and ultimately preventing neuronal 
cell death. This in turn would prevent memory loss and/or 
reduce the speed of cognitive deterioration.
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